Literature DB >> 7086691

Pharmacokinetics and metabolism of cytosine arabinoside in the central nervous system.

R Spector.   

Abstract

The pharmacokinetics and metabolism of [3H] cytosine arabinoside in the central nervous system were investigated. In vitro, the ability of rabbit brain slices and the isolated choroid plexus to accumulate [3H] cytosine arabinoside from artificial cerebrospinal fluid (CSF) containing 5 nM [3H] cytosine arabinoside was studied. Although in both tissues the uptake of [3H] cytosine arabinoside was saturable, neither brain slices nor the isolated choroid plexus achieved tissue/medium ratios greater than 1.0 in 30 min. After 15-min incubations iin artificial CSF containing 5 nM [3H] cytosine arabinoside, 8 +/- 2 (S.E.M.;N = 3)% of the 3H within the choroid plexuses was [3H] cytosine arabinoside phosphates; after comparable 30-min incubations, 4 +/- 1 (N = 4)% of the 3H within brain slices was [3H] cytosine arabinoside phosphates. In vivo, 2 hr after the i.c.v. injection into rabbits of [3H] cytosine arabinoside and 0, 2 ro 20 mumol of unlabeled cytosine arabinoside, it was shown that: 1) high concentrations of cytosine arabinoside in the CSF decreased the clearance of cytosine arabinoside from the CSF; 2) cytosine arabinoside was taken up and phosphorylated by brain cells in all regions tested; and 3) although the phosphorylation of [3H] cytosine arabinoside in brain cells was saturable, a portion of the [3H] cytosine arabinoside in brain was phosphorylated to [3H] cytosine arabinoside triphosphate even when the i.c.v. injectate contained 20 mumol of unlabeled cytosine arabinoside.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7086691

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Non-cardiogenic pulmonary edema complicating intermediate and high-dose Ara C treatment for relapsed acute leukemia.

Authors:  U Jehn; N Göldel; R Rienmüller; W Wilmanns
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

2.  Release of insulin produced by the choroid plexis is regulated by serotonergic signaling.

Authors:  Caio Henrique Mazucanti; Qing-Rong Liu; Doyle Lang; Nicholas Huang; Jennifer F O'Connell; Simonetta Camandola; Josephine M Egan
Journal:  JCI Insight       Date:  2019-12-05

Review 3.  Cerebellar toxicity during cytarabine therapy associated with renal insufficiency.

Authors:  H Hasle
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.

Authors:  Yousif Matloub; Susan Lindemulder; Paul S Gaynon; Harland Sather; Mei La; Emmett Broxson; Rochelle Yanofsky; Raymond Hutchinson; Nyla A Heerema; James Nachman; Marilyn Blake; Linda M Wells; April D Sorrell; Margaret Masterson; John F Kelleher; Linda C Stork
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

Review 5.  Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis.

Authors:  Gudrun Fleischhack; Ulrich Jaehde; Udo Bode
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

6.  Identification and partial characterization of rabbit brain deoxyuridine 5'-triphosphatase.

Authors:  R Spector; B Boose
Journal:  Neurochem Res       Date:  1983-08       Impact factor: 3.996

7.  High dose Ara-C related leukoencephalopathy.

Authors:  T L Hwang; W K Yung; Y Y Lee; A Borit; W S Fields
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

8.  Central nervous system pharmacokinetics of high-dose cytosine arabinoside.

Authors:  J A Lopez; E Nassif; P Vannicola; J G Krikorian; R P Agarwal
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

9.  Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity.

Authors:  J L Abbruzzese; S Schmidt; M N Raber; J K Levy; A M Castellanos; S S Legha; I H Krakoff
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

10.  Modeling immune functions of the mouse blood-cerebrospinal fluid barrier in vitro: primary rather than immortalized mouse choroid plexus epithelial cells are suited to study immune cell migration across this brain barrier.

Authors:  Ivana Lazarevic; Britta Engelhardt
Journal:  Fluids Barriers CNS       Date:  2016-01-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.